SeekingAlpha.com (Free subscription) | 11/05/2009
Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...
PR News Wire (Free subscription) | 11/03/2009
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Market Watch (Free subscription) | 11/02/2009
BOSTON (MarketWatch) -- Drug stocks advanced in early trading Monday as shares of Human Genome Sciences leaped on the release of more positive Phase III clinical data for its new lupus drug Benlysta. The NYSE Arca Pharmaceutical Index was largely flat at 287.23. The NYSE Arca Biotechnology Index , meanwhile, jumped 3.7% to 852.14, propelled by Human Genome, which is the largest component percentage-wise...
Market Watch (Free subscription) | 11/02/2009
TEL AVIV (MarketWatch) -- Human Genome Sciences Inc. and GlaxoSmithKline Plc said that their potential lupus drug, Benlysta, met its primary endpoint in the second of two Phase III trials. Over 52 weeks, the drug, generically belimumab, plus standard of care "achieved a statistically significant improvement in patient-response rate" compared with placebo plus standard of care, the companies...
The Earth Times Online Newspaper (Free subscription) | 11/02/2009
ROCKVILLE, Md. & LONDON - Human Genome Sciences, Inc. (Nasdaq:HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SL
Business Wire (Free subscription) | 11/02/2009
ROCKVILLE, Md. & LONDON--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq:HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care...
Philadelphia Inquirer (Free subscription) | 10/29/2009
GlaxoSmithKline P.L.C. said third-quarter profit rose 30 percent after currency gains and orders for the Relenza flu drug boosted revenue. Vaccine sales declined because of a "phasing" of shipments, including swine flu shots.
Indy Star (Free subscription) | 10/28/2009
LONDON -- GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.
Miami Herald (Free subscription) | 10/28/2009
GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.
Examiner (Free subscription) | 10/28/2009
GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.
Seattle Times (Free subscription) | 10/28/2009
GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.
San Fransisco Chronicle (Free subscription) | 10/28/2009
GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final... Sponsored Topics: GlaxoSmithKline - Swine influenza - Zanamivir - Health - Pharmaceutical industry
Radon Mitigation Pittsburgh (Free subscription) | 10/27/2009
( EMAILWIRE.COM , October 27, 2009 ) Dallas, TX - SuperGen, Inc. (NASDAQ:SUPG) surged 13.45% or $0.32 to close at $2.70 in trade today on over 1.23 million shares after today the company reported financial results for the third quarter and nine months ended September 30, 2009.Total revenues for the 2009 third quarter were $10.4 million, compared with $10.2 million for the same prior year period. Total...
Red Orbit (Free subscription) | 10/24/2009
The World Health Organization said on Friday that around 5,000 people have reportedly died from the swine flu since it emerged earlier this year.The figure is considered an underestimate because most countries have stopped keeping count of individual swine flu cases.The infection rate is lower in most European countries, but in Britain, Belgium, Holland and Norway the number of cases is very high.WHO...
Click here to see all comments
WARNING!!!
Is this a form of population control by the government? Did the government seize control of this most needed H1N1 vaccine to help wipe out some of the...
MarketIntelligenceCenter.com (Free subscription) | 10/23/2009
GlaxoSmithKline PLC (GSK) was downgraded today by analysts at Jefferies & Co. and the stock is now at $40.16, down $1.38 (-3.32%) on volume of 1,269,091 shares traded. The brokerage reduced GSK to Hold from Buy. Over the last 52 weeks the stock has ranged from a low of $27.15 to a high of $42.18. GlaxoSmithKline PLC stock has been showing support around $41.05 ...
The 3 latest articles published by users on GlaxoSmithKline plc :
tamilselvan1 | 08/16/2009
Drugmaker GlaxoSmithKline PLC said Friday it has started testing its swine flu vaccine in humans. Glaxo said it plans to conduct 16 clinical trials of its swine flu vaccine in more than 9,000 people in Europe and North America.
aarkstore | 08/05/2009
Introduction This databook is a detailed information resource covering all the key data points on Oral hygiene in South Africa. It includes comprehensive value volume segmentation and market share data. The databook supplies actual data to 2007 and full forecasts to 2012. Scope * Contains information on 5 categories: Toothpaste, Toothbrushes, Mouthwash, Dental floss and Denture care * Provides market...
aarkstore | 08/05/2009
Introduction This databook is a detailed information resource covering all the key data points on Oral hygiene in Finland. It includes comprehensive value volume segmentation and market share data. The databook supplies actual data to 2007 and full forecasts to 2012. Scope * Contains information on 5 categories: Toothpaste, Toothbrushes, Mouthwash, Dental floss and Denture care * Provides market value,...
Videos